Yüklüyor......
Modulation of Autophagy by Sorafenib: Effects on Treatment Response
The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepatocellular carcinoma (HCC), one of the most lethal types of cancer worldwide. However, the increase in the number of sorafenib tumor resistant cells reduces efficiency. A better knowledge of the intra...
Kaydedildi:
| Yayımlandı: | Front Pharmacol |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4896953/ https://ncbi.nlm.nih.gov/pubmed/27375485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00151 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|